Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight loss classes added to cardiac rehab may ease AFib symptoms

NCT ID NCT05600829

Symptom relief Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding group weight-loss classes to standard cardiac rehabilitation helps people with atrial fibrillation and obesity lose at least 10% of their body weight. About 120 adults will take part, with half getting the extra classes. The goal is to see if this combination reduces AFib symptoms and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral weight-loss treatment (group therapy sessions)
What this could lead to
If it works, this could offer a practical way for people with atrial fibrillation and obesity to lose weight and reduce uncomfortable heart symptoms.
What could go wrong
This is a small, early-stage trial with 120 participants, so results may not apply to everyone. Weight loss can be hard to maintain, and the program requires a big time commitment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults of age ≥18 years * Symptomatic paroxysmal or persistent atrial fibrillation or atrial flutter * Classified as obese (BMI ≥30 kg/m2) * Have a sedentary lifestyle (not currently meeting basic physical activity targets of ≥150 minutes/week) * Ability to speak and write in English * Willingness to be referred to a behavioural weight loss treatment (BWLT) * At least one of the following: obstructive sleep apnea, diabetes, hypertension, heart failure, dyslipidemia, CAD, peripheral artery, or cerebrovascular disease. Exclusion Criteria: * Longstanding-persistent (defined as ≥ 3 years continuous AF) or permanent AF * Uncontrolled coronary artery disease * Completed a CR program within the previous year * Currently enrolled in a structured behavioural weight loss program * Currently scheduled to receive catheter ablation in AF * Currently taking GLP-1 receptor agonist or * Received bariatric surgery in the previous year prior to enrollment OR scheduled for bariatric surgery during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Obesity

Contacts and locations

Locations

  • Behavioural Medicine Lab

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.